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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPERChannelopathies: Clinical Impact of Genetics 169
Peter J. Schwartz, Michael J. Ackerman, Alfred L. George, Jr, Arthur A. M. Wilde
In this state-of-the-art paper, Schwartz and colleagues review the impact of genetics and
genetic testing on 3 cardiac channelopathies: long QT syndrome, catecholaminergic
polymorphic ventricular tachycardia, and Brugada syndrome. Optimal use of genetic testing
for the management of patients, potential limitation of these tests, and medico-legal
implications are discussed. The effects of genotype on clinical manifestation, risk
stratiﬁcation, and response to therapy are also reviewed.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGYBiodegradable or Durable Polymer Coronary Stents 181
Masahiro Natsuaki, Ken Kozuma, Takeshi Morimoto, Kazushige Kadota, Toshiya Muramatsu,
Yoshihisa Nakagawa, Takashi Akasaka, Keiichi Igarashi, Kengo Tanabe, Yoshihiro Morino,
Tetsuya Ishikawa, Hideo Nishikawa, Masaki Awata, Mitsuru Abe, Hisayuki Okada,
Yoshiki Takatsu, Nobuhiko Ogata, Kazuo Kimura, Kazushi Urasawa, Yasuhiro Tarutani,
Nobuo Shiode, Takeshi Kimura, on behalf of the NEXT Investigators
Natsuaki and colleagues report on the NEXT trial designed to evaluate noninferiority of
biolimus-eluting stent (BES) (n ¼ 1,617) relative to everolimus-eluting stent (EES) (n ¼
1,618). At 1 year, the primary efﬁcacy endpoint of target lesion revascularization occurred in
67 patients (4.2%) in the BES group and in 66 patients (4.2%) in the EES group
demonstrating noninferiority of BES relative to EES. Angiographic substudy enrolling 528
patients demonstrated noninferiority of BES relative to EES regarding primary angiographic
endpoint of in-segment late loss (0.03  0.39 mm vs. 0.06  0.45 mm) at 266  43 days
after stent implantation. Deﬁnite stent thrombosis was low (0.25% vs. 0.06%, p ¼ 0.18). The
authors conclude that 1-year clinical and angiographic outcome after BES implantation
was noninferior and not different from EES implantation in a mostly stable coronary artery
disease population.(continued on page A-22)
JULY 16, 2013 (continued) A-22CARDIOMETABOLIC RISKHysterectomy and Cardiovascular Risk 191
Karen A. Matthews, Carolyn J. Gibson, Samar R. El Khoudary, Rebecca C. Thurston
Evidence suggests that hysterectomy with or without oophorectomy may increase the risk for
cardiovascular disease (CVD). Matthews and colleagues compare the changes in risk
factor for CVD leading up to and following hysterectomy with or without bilateral
oophorectomy with the changes observed to and following natural menopause. A total of
3,302 pre-menopausal women not using hormone therapy (age 42 to 52 years) were followed
annually over 11 years for social-demographic characteristics, menopausal status, surgeries,
body mass index, medication use, lifestyle factors, lipids, blood pressure, insulin resistance,
and hemostatic and inﬂammatory factors. A total of 1,769 women reached natural
menopause, 77 women had hysterectomy with ovarian conservation, and 106 women had
hysterectomy with bilateral oophorectomy. Multivariable analysis showed that annual
changes in CVD risk did not vary in groups. The authors conclude that women who have
surgical menopause in their 40s and 50s are not at greater risk for increase in CVD risk
compared to women who had natural menopause.CARDIOMETABOLIC RISKBinge Drinking and Vascular Function 201
Melissa Goslawski, Mariann R. Piano, Jing-Tan Bian, Emily C. Church, Mary Szczurek,
Shane A. Phillips
This paper reports on a study that was designed to test the hypothesis that young binge
drinkers have impaired macrovascular and microvascular function compared to controls.
Cardiovascular proﬁle, brachial artery endothelial-dependent ﬂow-mediated vasodilation
(FMD), ﬂow-independent nitroglycerine (NTG)-mediated dilation, and vasoreactivity of
resistance arteries (isolated from gluteal fat biopsies) were evaluated in binge drinkers (BD)
(>4 to 5 drinkers in 2 h) and abstainers (A) controls. FMD and NTG-mediated dilation
were signiﬁcantly lower in the BD group (FMD: 8.4  0.7%, p ¼ 0.022; NTG: 19.6  2%,
p ¼ 0.009) than in the A group (FMD 11  0.7%; NTG 28.6  2%). Acetylcholine and
sodium nitroprusside induced dilation in resistance arteries was not different between groups
but endothelin-1 induced constriction was enhanced in the BD group. Binge drinking is
associated with alterations in macrovascular and microvascular function and may be a risk for
future cardiovascular disease.
Editorial Comment: Robert A. Vogel, p. 208(continued on page A-23)
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Darren Mylotte, Ruben L. J. Osnabrugge, Stephan Windecker, Thierry Lefèvre, Peter de Jaegere,
Raban Jeger, Peter Wenaweser, Francesco Maisano, Neil Moat, Lars Søndergaard, Johan Bosmans,
Rui C. Teles, Giuseppe Martucci, Ganesh Manoharan, Eulogio Garcia, Nicolas M. Van Mieghem,
A. Pieter Kappetein, Patrick W. Serruys, Ruediger Lange, Nicolo Piazza
Mylotte and colleagues describe the adoption of transcatheter aortic valve replacement
(TAVR) in Western Europe since 2007 and 2011. A total of 34,317 patients underwent
TAVR. Signiﬁcant correlation was found between TAVR use and healthcare spending per
capita (r ¼ 0.80, p ¼ 0.005), however, weighted average TAVR penetration was low, at
17.9%. TAVR speciﬁc reimbursement systems were associated with higher TAVR use than
restricted systems (698  232 vs. 213  112 implants per million 75 years, p ¼ 0.002) The
authors conclude that TAVR is underutilized in high surgical risk patients with severe aortic
stenosis and national economic indices, and reimbursement strategies are closely linked with
TAVR use.
Editorial Comment: John G. Webb, Marco Barbanti, p. 220HEART VALVE DISEASEMalignant Bileaﬂet Mitral Valve Prolapse 222Chenni S. Sriram, Faisal F. Syed, M. Eric Ferguson, Jonathan N. Johnson, Maurice Enriquez-Sarano,
Frank Cetta, Bryan C. Cannon, Samuel J. Asirvatham, Michael J. Ackerman
The role of mitral valve prolapsed (MVP) in sudden unexpected death in the young remains
controversial. Sriram and colleagues investigate the prevalence of MVP and its association
with ventricular arrhythmias in a cohort with unexplained out-of-hospital cardiac arrest
(OHCA). Of 1,200 patients evaluated July 2000 to December 2009, 24 (16 females, median
age 33.5 years) had OHCA (i.e., ischemic/cardiomyopathy/channelopathy negative).
Bileaﬂet MVP was found in 10 (42%) patients. Compared to controls, patients with bileaﬂet
MVP were mostly females (9 of 10 vs. 7 of 14, p ¼ 0.04), had higher prevalence of biphasic/
inverted T waves (7 of 9 vs. 4 of 14, p ¼ 0.04) and on holter interrogation had higher
prevalence of ventricular bigeminy (9 of 9 vs. 1 of 10, p < 0.0001), ventricular tachycardia
(7 of 9 [78%] vs. 1 of 10 [10%], p ¼ 0.006), and premature ventricular contractions (PVC)
originating from the outﬂow tract alternating with papillary muscle/fasicular region. On
follow-up, only bileaﬂet MVP was associated with ventricular ﬁbrillation recurrences
requiring implantable cardioverter-deﬁbrillator therapy. The authors have described a
malignant subset of MVP patients characterized by bileaﬂet MVP, female sex, and frequent
complex ventricular ectopy.(continued on page A-24)
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Mark I. Davis, Kristian B. Filion, David Zhang, Mark J. Eisenberg, Jonathan Aﬁlalo,
Ernesto L. Schiffrin, Dominique Joyal
Davis and colleagues conduct a systematic review and meta-analysis of published studies
evaluating the effect of sympathetic renal denervation (RDN) in patients with resistant
hypertension. In the controlled studies reviewed, there was reduction in mean systolic and
diastolic BP at 6 months of 28.9 and –11.0 mm Hg, respectively, in patients undergoing
RDN compared to medically treated patients (for both p < 0.0001). In uncontrolled studies
there was reduction in mean systolic and diastolic BP at 6 months of 25 and 10 mm Hg
(p < 0.00001) for RDN as compared to medical therapy. One renal artery dissection and
4 femoral pseudoaneurysms were reported. The authors conclude that RDN results in a
substantial reduction in mean BP at 6 months.HYPERTENSIONPost-PCI Troponin Elevation in ACS and Mortality 242Pierluigi Tricoci, Sergio Leonardi, Jennifer White, Harvey D. White, Paul W. Armstrong,
Gilles Montalescot, Robert P. Giugliano, C. Michael Gibson, Frans Van de Werf, Robert M. Califf,
Robert A. Harrington, Eugene Braunwald, Kenneth W. Mahaffey, L. Kristin Newby
In patients with non–ST-segment elevation myocardial infarction (NSTEMI) it is difﬁcult to
distinguish between cardiac troponin (cTn) elevations due to percutaneous coronary
intervention (PCI) or index myocardial infarction. Prognostic value of cTn is also unclear in
this setting. To further study the relationship, time, and cTn (indexed by upper limit of
normal [ULN]), data pairs were plotted for 10,199 NSTEMI patients undergoing PCI
(enrolled in the EARLY ACS and SYNERGY study). Peak cTn, post-PCI, and its
relationship with 1-year mortality was evaluated after adjusting for clinical variables. Patients
in whom post-PCI elevation of cardiac markers could not be excluded from index myocardial
infarction (MI) were excluded (n ¼ 4,427 [43%]). For the remainder (n ¼ 5,772 [57%]), in a
multivariable model, a 10 ULN increase in cTn post-PCI was associated with a 7% increase
in mortality. For each 1 ULN increase in CK-MB peak there was a 13% increase in 1-year
mortality. Tricoci and colleagues show the feasibility of differentiating post-PCI cTn
elevation from that of presenting MI and its association with 1-year mortality.
